Anti-CREBBP抗体(ab2832)
Key features and details
- Rabbit polyclonal to CREBBP
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
概述
-
产品名称
Anti-CREBBP抗体
参阅全部 CREBBP 一抗 -
描述
兔多克隆抗体to CREBBP -
宿主
Rabbit -
经测试应用
适用于: WB, IHC-P, ICC/IFmore details -
种属反应性
与反应: Mouse, Rat, Human
预测可用于: Non human primates
-
免疫原
Synthetic peptide corresponding to Human CREBBP aa 162-176.
Sequence:ATSSPATSQTGPGIC
(Peptide available asab4916)
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
存储溶液
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 99% PBS -
Concentration information loading... -
纯度
Immunogen affinity purified -
Primary antibody说明
Cyclic AMP-responsive enhancer binding protein (CREB) binding protein (CBP) and p300 are closely related transcriptional coactivators that have been shown to directly interact with many different DNA-binding transcription factors including nuclear hormone receptors, CREB (cyclic AMP-responsive enhancer binding protein), c-Fos, c-Jun/v-Jun, c-Myb/v-Myb, TFIIB and MyoD.Both CBP and p300 have been shown to display histone acetyltransferase (HAT) activity, capable of acetylating all four core histone particles in nucleosomes.As a result of HAT activity, it has been suggested CBP and p300 may play a direct role in activating chromatin for transcription.Single point mutations in CBP have been proposed as causative factors in the developmental abnormalities of Rubinstein-Taybi syndrome (RTS).Although both CBP and p300 appear to function similarly, the inability of p300 to rescue CBP malfunction iRTS suggests intrinsic functional differences between CBP and p300. -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
ChIP Related Products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
应用
Our Abpromise guarantee covers the use of ab2832 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| 应用 | Ab评论 | 说明 |
|---|---|---|
| WB | Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 265 kDa (predicted molecular weight: 265 kDa). | |
| IHC-P | 1/1000 - 1/5000. | |
| ICC/IF | 1/100. |
靶标
-
功能
Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300. -
疾病相关
Note=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with MYST3/MOZ; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with MYST4/MORF. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription.
Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies. -
序列相似性
Contains 1 bromo domain.
Contains 1 KIX domain.
Contains 2 TAZ-type zinc fingers.
Contains 1 ZZ-type zinc finger. -
结构域
The KIX domain mediates binding to HIV-1 Tat. -
翻译后修饰
Methylation of the KIX domain by CARM1 blocks association with CREB. This results in the blockade of CREB signaling, and in activation of apoptotic response.
Phosphorylated upon DNA damage, probably by ATM or ATR.
Sumoylation negatively regulates transcriptional activity via the recruitment of DAAX. -
细胞定位
Cytoplasm. Nucleus. Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus. - Information by UniProt
-
数据库链接
- Entrez Gene: 1387 Human
- Entrez Gene: 12914 Mouse
- Entrez Gene: 54244 Rat
- Omim: 600140 Human
- SwissProt: Q92793 Human
- SwissProt: P45481 Mouse
- SwissProt: Q6JHU9 Rat
- Unigene: 459759 Human
see all -
别名
- CBP antibody
- CBP_HUMAN antibody
- CREB binding protein antibody
see all
图片
-
Immunocytochemistry/ Immunofluorescence - Anti-CREBBP antibody (ab2832)Immunofluorescent analysis of MCF-7 cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with DAPI (blue). The nuclear localization of KAT3A/CBP can be observed (green).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CREBBP antibody (ab2832)IHC image of CREBBP staining in human pancreas formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab2832, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
Immunocytochemistry/ Immunofluorescence - Anti-CREBBP antibody (ab2832)Immunofluorescent analysis of HeLa cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with DAPI (blue). The nuclear localization of KAT3A/CBP can be observed (green).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CREBBP antibody (ab2832)Immunohistochemical analysis of FFPE mouse colon tissue, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Heat antigen retrieval performed with 10mM Sodium Citrate (pH 6) for 8-15 minutes. Tissue blocked with 3% H2O2-methanol for 15 minutes at room temperature. Incubation with ab2832 diluted 1/2000 in 3% BSA-PBS overnight at 4°C. Counterstaining with hematoxylin.
-
Immunocytochemistry/ Immunofluorescence - Anti-CREBBP antibody (ab2832)Immunofluorescent analysis of NIH-3T3 cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Nuclei were stained with DAPI (blue).
-
Western blot - Anti-CREBBP antibody (ab2832)ab2832 using HeLa cell lysate. ab2832 using HeLa cell lysate.
实验方案
文献 (47)
ab2832 被引用在 47 文献中.
- Lee W et al. Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor ß-induced protein and improves survival in sepsis. Biomaterials 246:120000 (2020). PubMed: 32247936
- Xian D & Zhao Y LncRNA KCNQ1OT1 enhanced the methotrexate resistance of colorectal cancer cells by regulating miR-760/PPP1R1B via the cAMP signalling pathway. J Cell Mol Med 23:3808-3823 (2019). PubMed: 30997746
- Ding H et al. Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss. Cell Rep 27:3331-3344.e6 (2019). PubMed: 31189115
- Dong H et al. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer 18:3 (2019). PubMed: 30621694
- Chen F et al. lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/ß-catenin pathway in oral squamous cell carcinoma. Int J Oncol 54:1183-1194 (2019). PubMed: 30720068
